Multicenter, open-label, study to evaluate safety,tolerability, pharmacokinetics and, pharmacodynamics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared with enalapril in pediatric patients from1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction)

drug protocol number
CLCZ696B2319
drug sponsor
Novartis
drug study
Entresto
drug trial site
KFSH&RC-R , KFSH-D
drug status
Completed
drug phase